STORM Therapeutics
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Building 1000 Cambridge Research Park, W...Phone Number
+44 1223804174Website
www.stormtherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About STORM Therapeutics
STORM Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies that target RNA-modifying enzymes to treat cancer and other serious diseases. Its research aims to reprogram disease-driving cellular processes by inhibiting key biological regulators involved in tumor development and progression. The company advances innovative drug candidates through clinical development to address areas of high unmet medical need.Explore more
STORM Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is STORM Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once STORM Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if STORM Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if STORM Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when STORM Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at STORM Therapeutics
Check out if STORM Therapeutics is spiking on competitors!
STORM Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on STORM Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at STORM Therapeutics
Find 2 more new buyers
Compare Similar Companies to STORM Therapeutics
Compare insights from companies similar to STORM Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
STORM Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
STORM Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about STORM Therapeutics.
STORM Therapeutics financials insights
Gather financial insights about STORM Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Seed
$748K
2016
Series A
$16M
2022
Series B
$30M
2026
Series C
$56M
STORM Therapeutics Tech Stack
A closer look at the technologies used by STORM Therapeutics
See more technologies
Most Recent Scoops
Funding
Funding
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
STORM Therapeutics News & Media
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
STORM Therapeutics announces a $56 million Series C financing to support the advancement of STC-15 in a Phase 2 study.STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
CAMBRIDGE, England and SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida Biosciences Inc. (AlidaBio), a...STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced the appointment of accomplished cancer biologist Dr. Eric Martin, PhD, as Chief...STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer
STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor Collaboration enables Phase 1b/2 study with STORM's lead product, STC-15 in combination with Coherus's next generation PD-1 inhibitor, LOQTORZI®...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding STORM Therapeutics
Sign Up For FreeTo access detailed company insights
STORM Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies that target RNA-modifying enzymes to treat cancer and other serious diseases. Its research aims to reprogram disease-driving cellular processes by inhibiting key biological regulators involved in tumor development and progression. The company advances... Read More
